Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice

Biological Chemistry

Volumn 390, Issue 7, 2009, Pages 611-618

  Ryan, Sean O ^a   Vlad, Anda M ^a   Islam, Kazi ^a   Gariépy, Jean ^b   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Glycoprotein; Tn antigen; Tumor antigen; Vaccine

Indexed keywords

AMINO ACID; ANTIBODY; EPITOPE; GLYCOPEPTIDE; MUCIN 1; TUMOR ANTIGEN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; GLYCOSYLATION; HYBRIDOMA; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; VARIABLE NUMBER OF TANDEM REPEAT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; B-LYMPHOCYTES; CROSS REACTIONS; DENDRITIC CELLS; EPITOPES; GLYCOPEPTIDES; GLYCOSYLATION; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUCIN-1; SELF TOLERANCE; T-LYMPHOCYTES; VACCINATION;

MUS; MUS MUSCULUS;

EID: 68149166302     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2009.070     Document Type: Article

References (36)

1. Bos, R., van Duikeren, S., Morreau, H., Franken, K., Schumacher, T.N.M., Haanen, J.B., van der Burg, S.H., Melief, C.J.M., and Offringa, R. (2008). Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68, 8446-8455.
2. Brokx, R.D., Revers, L., Zhang, Q., Yang, S., Mal, T.K., Ikura, M., and Gariepy, J. (2003). Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Biochemistry 42, 13817-13825.
3. Bruder, D., Westendorf, A.M., Hansen, W., Prettin, S., Gruber, A.D., Qian, Y., von Boehmer, H., Mahnke, K., and Buer, J. (2005). On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54, 3395-3401.
4. Deck, M.B., Sjolin, P., Unanue, E.R., and Kihlberg, J. (1999). MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. J. Immunol. 162, 4740-4744.
5. Ding, C., Wang, L., Marroquin, J., and Yan, J. (2008). Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 112, 2817-2825.
6. Gerloni, M., Castiglioni, P., and Zanetti, M. (2005). The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J. Immunol. 175, 6551-6559.
7. Goydos, J.S., Elder, E., Whiteside, T.L., Finn, O.J., and Lotze, M.T. (1996). A Phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-304.
8. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). Dendritic cells induce peripheral T cell unresponsive- ness under steady state conditions in vivo. J. Exp. Med. 194, 769-780.
9. Hiltbold, E.M., Vlad, A.M., Ciborowski, P., Watkins, S.C., and Finn, O.J. (2000). The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165, 3730-3741.
10. Jerome, K.R., Barnd, D.L., Bendt, K.M., Boyer, C.M., Taylor- Papadimitriou, J., McKenzie, I.F.C., Bast, R.C. Jr., and Finn, O.J. (1991). Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51, 2908-2916.
11. Jerome, K.R., Domenech, N., and Finn, O.J. (1993). Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151, 1654-1662.
12. + T cells in anti-tumor immune responses. Immunol. Rev. 222, 129-144.
13. Kretschmer, K., Apostolou, I., Hawiger, D., Khazaie, K., Nus-senzweig, M.C., and von Boehmer, H. (2005). Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6, 1219-1227.
14. Lepisto, A.J., Moser, A.J., Zeh, H., Lee, K., Bartlett, D., Mc-Kolanis, J.R., Geller, B.A., Schmotzer, A., Potter, D.P., Whiteside, T., et al. (2008). A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6, 955-964.
15. Napoletano, C., Rughetti, A., Agervig Tarp, M.P., Coleman, J., Bennett, E.P., Picco, G., Sale, P., Denda-Nagai, K., Irimura, T., Mandel, U., et al. (2007). Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactosetype C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res. 67, 8358-8367.
16. Nichols, L.A., Chen, Y., Colella, T.A., Bennett, C.L., Clausen, B.E., and Engelhard, V.H. (2007). Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J. Immunol. 179, 993-1003.
17. Ninkovic, T., Kinarsky, L., Engelmann, K., Pisarev, V., Sherman, S., Finn, O.J., and Hanisch, F.-G. (2009). Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol. Immunol., in press.
18. Przetak, M., Chow, J., Cheng, H., Rose, J., Hawkins, L.D., and Ishizaka, S.T. (2003). Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine 21, 961-970.
19. Ramanathan, R.K., Lee, K.M., McKolanis, J., Hitbold, E., Schraut, W., Moser, A.J., Warnick, E., Whiteside, T., Osborne, J., Kim, H., et al. (2005). Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264.
20. Reilly, R.T., Gottlieb, M.B.C., Ercolini, A.M., Machiels, J.-P.H., Kane, C.E., Okoye, F.I., Muller, W.J., Dixon, K.H., and Jaffee, E.M. (2000). HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60, 3569-3576.
21. Rowse, G.J., Tempero, R.M., VanLith, M.L., Hollingsworth, M.A., and Gendler, S.J. (1998). Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58, 315-321.
22. Ryan, S.O., Gantt, K.R., and Finn, O.J. (2007). Tumor antigen-based immunotherapy and immunoprevention of cancer. Int. Arch. Allergy Immunol. 142, 179-189.
23. Saeland, E., van Vliet, S., Bäckström, M., van den Berg, V., Geijtenbeek, T., Meijer, G., and van Kooyk, Y. (2007). The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol. Immunother. 56, 1225-1236.
24. Soares, M.M., Mehta, V., and Finn, O.J. (2001). Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563.
25. Sorensen, A.L., Reis, C.A., Tarp, M.A., Mandel, U., Ramachan-dran, K., Sankaranarayanan, V., Schwientek, T., Graham, R., Taylor-Papadimitriou, J., Hollingsworth, M.A., et al. (2006). Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16, 96-107.
26. Springer, G.F. (1997). Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 75, 594-602.
27. Tarp, M.A., Sorensen, A.L., Mandel, U., Paulsen, H., Burchell, J., Taylor-Papadimitriou, J., and Clausen, H. (2007). Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17, 197-209.
28. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161, 5500-5506.
29. Tsuiji, M., Fujimori, M., Ohashi, Y., Higashi, N., Onami, T.M., Hedrick, S.M., and Irimura, T. (2002). Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J. Biol. Chem. 277, 28892-28901.
30. Turner, M.S., Cohen, P.A., and Finn, O.J. (2007). Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178, 2787-2793.
31. Valladeau, J., Duvert-Frances, V., Pin, J.-J., Kleijmeer, M.J., Ait-Yahia, S., Ravel, O., Vincent, C., Vega, F. Jr., Helms, A., Gorman, D., et al. (2001). Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J. Immunol. 167, 5767-5774.
32. Vlad, A.M. and Finn, O.J. (2004). Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis. 20, 73-79.
33. Vlad, A.M., Muller, S., Cudic, M., Paulsen, H., Otvos, L. Jr., Hanisch, F.-G., and Finn, O.J. (2002). Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196, 1435-1446.
34. White, J., Blackman, M., Bill, J., Kappler, J., Marrack, P., Gold, D., and Born, W. (1989). Two better cell lines for making hybridomas expressing specific T cell receptors. J. Immunol. 143, 1822-1825.
35. Xu, Y., Gendler, S.J., and Franco, A. (2004). Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 199, 707-716.
36. Zarling, A.L., Polefrone, J.M., Evans, A.M., Mikesh, L.M., Sha-banowitz, J., Lewis, S.T., Engelhard, V.H., and Hunt, D.F. (2006). Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 103, 14889-14894.